Home/Pipeline/GF-CART01

GF-CART01

B cell malignancies

PreclinicalActive

Key Facts

Indication
B cell malignancies
Phase
Preclinical
Status
Active
Company

About GenomeFrontier Therapeutics

Taiwan biotech leveraging virus‑free gene‑editing platforms to create CAR‑T/TCR‑T cell therapies for cancer.

View full company profile

Therapeutic Areas